Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CCKAR | P32238 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034340 | 0.92 | EPHX2 (0.38) | KCNK3KCNK9IRAK4EPHX2MAPT | |
| SCHEMBL15019969 | 0.90 | CFTR (0.40) | KCNK3KCNK9SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL15046954 | 0.82 | EPHX2 (0.39) | KCNK3KCNK9IRAK4EPHX2MAPT | |
| SCHEMBL15034041 | 0.81 | GRM5 (0.39) | KCNK3KCNK9SMN1; SMN2IRAK4EPHX2 | |
| SCHEMBL15034128 | 0.81 | CFTR (0.42) | KCNK3KCNK9SMN1; SMN2IRAK4CFTR | |
| SCHEMBL15034026 | 0.81 | CFTR (0.38) | KCNK3KCNK9ALDH1A1IRAK4CFTR | |
| SCHEMBL15019975 | 0.80 | GRM5 (0.41) | KCNK3KCNK9SMN1; SMN2IRAK4EPHX2 | |
| SCHEMBL15034189 | 0.79 | CFTR (0.37) | KCNK3KCNK9SMN1; SMN2IRAK4EPHX2 | |
| SCHEMBL15034190 | 0.79 | CFTR (0.37) | KCNK3KCNK9SMN1; SMN2IRAK4EPHX2 | |
| SCHEMBL15019926 | 0.78 | MGLL (0.36) | KCNK3KCNK9SMN1; SMN2ALDH1A1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883789-B2 | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-8883789-B2 | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20130158042-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158042-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158042-A1 | NOVEL COMPOUNDS | GRM5, GRIK5, GRM1 | KCNK3 1154/4885KCNK9 1745/4885SMN1; SMN2 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.